Mezzion Pharma Co.,Ltd. (KOSDAQ:140410)
91,600
+100 (0.11%)
At close: Mar 20, 2026
Mezzion Pharma Revenue
Mezzion Pharma had revenue of 2.13B KRW in the quarter ending September 30, 2025, a decrease of -5.89%. This brings the company's revenue in the last twelve months to 7.75B, down -44.95% year-over-year. In the year 2024, Mezzion Pharma had annual revenue of 8.61B, down -72.85%.
Revenue (ttm)
7.75B
Revenue Growth
-44.95%
P/S Ratio
351.84
Revenue / Employee
439.42M
Employees
18
Market Cap
2.78T
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 8.61B | -23.11B | -72.85% |
| Dec 31, 2023 | 31.72B | 994.76M | 3.24% |
| Dec 31, 2022 | 30.73B | 4.07B | 15.28% |
| Dec 31, 2021 | 26.65B | -1.98B | -6.92% |
| Dec 31, 2020 | 28.63B | 10.71B | 59.79% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Samsung Biologics | 4.56T |
| Celltrion | 4.16T |
| Hanmi Science | 1.34T |
| Hugel | 425.10B |
| ST Pharm | 318.32B |
| Celltrion Pharm | 274.73B |
| Sam Chun Dang Pharm. | 220.74B |
| ALTEOGEN | 202.18B |